Source:http://linkedlifedata.com/resource/pubmed/id/11302255
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2001-4-13
|
| pubmed:abstractText |
Differential display polymerase chain reaction analysis was used to compare five differentiation states of the O-2A progenitor-like cell line CG4: progenitor cells and cells at 12 h or 4 days after the induction of differentiation into oligodendrocytes or astrocytes. This led to the identification of 52 sequence tags that were expressed differentially with cellular phenotype. One sequence was upregulated during differentiation of CG4 cells and represented a novel gene that we named SETA (SH3 domain-containing gene expressed in tumorigenic astrocytes). This gene encodes an SH3 domain-containing adapter protein with sequence similarity to the CD2AP (CD2 adapter protein) and CMS (Cas ligand with multiple Src homology) genes. SETA mRNA was expressed at high levels in the developing rat brain but was barely detectable in the normal adult rat or human brain. However, SETA mRNA was found in approximately one half of the human gliomas tested, including astrocytomas grades II, III, and IV, as well as oligodendrogliomas, mixed oligoastrocytomas, and human glioma-derived cell lines. A rat glioma generated by treatment with the alkylating carcinogen ethylnitrosourea on postnatal day 1 and a derived cell line also expressed SETA mRNA. Furthermore, in an in vitro model of astrocytoma progression based on p53-/- astrocytes, expression of SETA was restricted to cells that are tumorigenic.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1522-8517
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6-15
|
| pubmed:dateRevised |
2008-11-20
|
| pubmed:meshHeading |
pubmed-meshheading:11302255-Animals,
pubmed-meshheading:11302255-Animals, Newborn,
pubmed-meshheading:11302255-Astrocytes,
pubmed-meshheading:11302255-Brain,
pubmed-meshheading:11302255-Brain Neoplasms,
pubmed-meshheading:11302255-Cell Line,
pubmed-meshheading:11302255-Central Nervous System Neoplasms,
pubmed-meshheading:11302255-DNA, Complementary,
pubmed-meshheading:11302255-Data Display,
pubmed-meshheading:11302255-Embryonic and Fetal Development,
pubmed-meshheading:11302255-Glioma,
pubmed-meshheading:11302255-Humans,
pubmed-meshheading:11302255-Neoplasm Proteins,
pubmed-meshheading:11302255-Nerve Tissue Proteins,
pubmed-meshheading:11302255-Neuroglia,
pubmed-meshheading:11302255-Oligodendroglia,
pubmed-meshheading:11302255-Polymerase Chain Reaction,
pubmed-meshheading:11302255-Rats,
pubmed-meshheading:11302255-Stem Cells
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes.
|
| pubmed:affiliation |
Ludwig Institute for Cancer Research, University of California San Diego, La Jolla 92093-0660, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|